Loading clinical trials...

WITHDRAWNNA

Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

Calcium Channel Blockers in Nitric Oxide Non-responder Pulmonary Arterial Hypertension.

NCT01645826•University of South Florida

Summary

The purpose of this study is to determine if cardizem is effective in the treatment of nitric oxide non-responder pulmonary arterial hypertension.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adult participants
•Confirmed WHO class I pulmonary arterial hypertension
•Nitric Oxide Non-Responders on right heart catheterization
•Experience dyspnea, NYHA III-IV with poor oxygenation and quality of life despite standard treatments
•Must be able to swallow medications

Exclusion Criteria

•Pulmonary hypertension secondary to 1) elevations in pulmonary venous pressures (i.e. left heart disease), 2) chronic hypoxemic states from lung diseases such as COPD, sleep-disordered breathing, alveolar hypoventilation disorders, chronic exposure to high altitude and developmental abnormalities 3) chronic thromboembolic disease, 4) sarcoidosis, 5) Lymphangiomyomatosis, 5) Pulmonary Langerhans Cell Histiocytosis
•Already on a calcium channel blocker
•Systolic blood pressure less than 90
•Heart rate less than 55
•Pregnant
•Cannot sign informed consent
•Right heart failure
•Pulmonary Veno-occlusive disease

Locations (1)

University of South Florida

Tampa, Florida, United States

Key Dates

Start Date

July 1, 2012

Primary Completion Date

September 1, 2014

Completion Date

September 1, 2014

Last Updated

November 20, 2018

Conditions

Idiopathic Pulmonary Arterial HypertensionPrimary Pulmonary HypertensionPulmonary Arterial HypertensionFamilial Primary Pulmonary Hypertension

Interventions

Diltiazem Hydrochloride

DRUG

Sugar Pill

DRUG

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110

Healthy Volunteers, Pulmonary Arterial Hypertension

View study

RECRUITINGPHASE3

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

NCT07218029

Pulmonary Arterial Hypertension

View study

RECRUITINGPHASE1

A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 20, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy Study of Cardizem in Pulmonary Arterial Hypertension

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)

A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension

COMPERA / COMPERA-KIDS

The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study

China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization